This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
UMN Pharma, Inc.
Drug Names(s): Norovirus VLP
Description: UMN-2002 is a recombinant norovirus virus-like particle (VLP) antigen vaccine for the prevention of norovirus.
UMN Pharma and Daiichi Sankyo
In February 2014, Daiichi Sankyo and UMN Pharma announced the conclusion of a collaborative research agreement for norovirus vaccine. Under the terms of the agreement, UMN Pharma will provide Daiichi Sankyo with recombinant norovirus Virus-Like Particle (VLP) antigen which has been produced by a cell-culture manufacturing method employing the Baculovirus Expression Vector System (BEVS). Daiichi Sankyo will conduct a basic research to determine the possibility to develop norovirus vaccine with a novel device. Daiichi Sankyo and UMN Pharma will negotiate further collaboration for the development if results of the collaborative research meet certain evaluation criteria. In addition, UMN Pharma will provide Daiichi Sankyo with norovirus VLP antigen exclusively and grant the right to negotiate exclusively for further partnership during the collaborative research agreement period.
Partners: Daiichi Sankyo Co., Ltd.
Additional information available to subscribers only: